Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: WNT10A

Gene summary for WNT10A

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

WNT10A

Gene ID

80326

Gene nameWnt family member 10A
Gene AliasOODD
Cytomap2q35
Gene Typeprotein-coding
GO ID

GO:0001942

UniProtAcc

Q9GZT5


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
80326WNT10ALZE24THumanEsophagusESCC5.76e-032.38e-010.0596
80326WNT10AP2T-EHumanEsophagusESCC5.13e-451.27e+000.1177
80326WNT10AP4T-EHumanEsophagusESCC6.51e-071.29e-010.1323
80326WNT10AP8T-EHumanEsophagusESCC3.51e-058.60e-020.0889
80326WNT10AP11T-EHumanEsophagusESCC1.64e-076.93e-010.1426
80326WNT10AP12T-EHumanEsophagusESCC8.72e-134.51e-010.1122
80326WNT10AP16T-EHumanEsophagusESCC2.76e-081.39e-010.1153
80326WNT10AP17T-EHumanEsophagusESCC5.75e-042.31e-010.1278
80326WNT10AP20T-EHumanEsophagusESCC8.38e-277.40e-010.1124
80326WNT10AP21T-EHumanEsophagusESCC2.02e-409.32e-010.1617
80326WNT10AP22T-EHumanEsophagusESCC1.34e-026.14e-020.1236
80326WNT10AP26T-EHumanEsophagusESCC5.96e-103.09e-010.1276
80326WNT10AP27T-EHumanEsophagusESCC1.14e-113.65e-010.1055
80326WNT10AP28T-EHumanEsophagusESCC1.89e-023.01e-010.1149
80326WNT10AP30T-EHumanEsophagusESCC2.59e-075.47e-010.137
80326WNT10AP31T-EHumanEsophagusESCC3.53e-377.26e-010.1251
80326WNT10AP36T-EHumanEsophagusESCC3.38e-044.03e-010.1187
80326WNT10AP37T-EHumanEsophagusESCC2.09e-245.77e-010.1371
80326WNT10AP44T-EHumanEsophagusESCC1.83e-021.02e-010.1096
80326WNT10AP49T-EHumanEsophagusESCC4.53e-046.19e-010.1768
Page: 1 2 3 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0048732111EsophagusESCCgland development269/8552436/187237.81e-122.95e-10269
GO:001605517EsophagusESCCWnt signaling pathway268/8552444/187232.32e-106.58e-09268
GO:019873817EsophagusESCCcell-cell signaling by wnt269/8552446/187232.41e-106.79e-09269
GO:00435888EsophagusESCCskin development163/8552263/187236.48e-081.14e-06163
GO:000854410EsophagusESCCepidermis development193/8552324/187232.87e-074.19e-06193
GO:00715599EsophagusESCCresponse to transforming growth factor beta157/8552256/187232.95e-074.23e-06157
GO:006007016EsophagusESCCcanonical Wnt signaling pathway180/8552303/187239.15e-071.17e-05180
GO:00715609EsophagusESCCcellular response to transforming growth factor beta stimulus151/8552250/187231.78e-062.10e-05151
GO:00488638EsophagusESCCstem cell differentiation122/8552206/187235.95e-054.59e-04122
GO:00487628EsophagusESCCmesenchymal cell differentiation133/8552236/187235.94e-043.22e-03133
GO:00224043EsophagusESCCmolting cycle process53/855284/187239.62e-044.88e-0353
GO:00224053EsophagusESCChair cycle process53/855284/187239.62e-044.88e-0353
GO:0001942EsophagusESCChair follicle development51/855281/187231.27e-036.14e-0351
GO:0098773EsophagusESCCskin epidermis development53/855285/187231.43e-036.77e-0353
GO:00423033EsophagusESCCmolting cycle64/8552107/187232.24e-039.85e-0364
GO:00426333EsophagusESCChair cycle64/8552107/187232.24e-039.85e-0364
GO:00604856EsophagusESCCmesenchyme development156/8552291/187233.76e-031.53e-02156
GO:20000274EsophagusESCCregulation of animal organ morphogenesis71/8552125/187237.97e-032.84e-0271
GO:004873220Oral cavityOSCCgland development226/7305436/187232.78e-085.39e-07226
GO:001605510Oral cavityOSCCWnt signaling pathway227/7305444/187231.10e-071.87e-06227
Page: 1 2 3 4 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05022210EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa05010210EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa0516510EsophagusESCCHuman papillomavirus infection215/4205331/84657.86e-097.12e-083.65e-08215
hsa0520529EsophagusESCCProteoglycans in cancer138/4205205/84651.79e-071.40e-067.15e-07138
hsa0522518EsophagusESCCHepatocellular carcinoma109/4205168/84654.27e-051.88e-049.64e-05109
hsa041505EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa0439018EsophagusESCCHippo signaling pathway92/4205157/84651.46e-023.31e-021.69e-0292
hsa0502238EsophagusESCCPathways of neurodegeneration - multiple diseases318/4205476/84656.10e-152.04e-131.05e-13318
hsa0501038EsophagusESCCAlzheimer disease263/4205384/84651.80e-145.47e-132.80e-13263
hsa0516515EsophagusESCCHuman papillomavirus infection215/4205331/84657.86e-097.12e-083.65e-08215
hsa0520537EsophagusESCCProteoglycans in cancer138/4205205/84651.79e-071.40e-067.15e-07138
hsa0522519EsophagusESCCHepatocellular carcinoma109/4205168/84654.27e-051.88e-049.64e-05109
hsa0415013EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa0439019EsophagusESCCHippo signaling pathway92/4205157/84651.46e-023.31e-021.69e-0292
hsa0501028Oral cavityOSCCAlzheimer disease244/3704384/84651.18e-153.60e-141.83e-14244
hsa0502228Oral cavityOSCCPathways of neurodegeneration - multiple diseases292/3704476/84651.60e-154.47e-142.28e-14292
hsa051659Oral cavityOSCCHuman papillomavirus infection200/3704331/84653.83e-104.93e-092.51e-09200
hsa0520526Oral cavityOSCCProteoglycans in cancer128/3704205/84654.00e-083.12e-071.59e-07128
hsa0522516Oral cavityOSCCHepatocellular carcinoma97/3704168/84651.63e-045.52e-042.81e-0497
hsa041504Oral cavityOSCCmTOR signaling pathway90/3704156/84652.87e-049.15e-044.66e-0490
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
WNT10AFZD10_LRP6WNT10A_FZD10_LRP6WNTEsophagusESCC
WNT10AFZD3_LRP6WNT10A_FZD3_LRP6WNTEsophagusESCC
WNT10AFZD4_LRP6WNT10A_FZD4_LRP6WNTEsophagusESCC
WNT10AFZD5_LRP6WNT10A_FZD5_LRP6WNTEsophagusESCC
WNT10AFZD6_LRP6WNT10A_FZD6_LRP6WNTEsophagusESCC
WNT10AFZD8_LRP6WNT10A_FZD8_LRP6WNTEsophagusESCC
WNT10AFZD4_LRP5WNT10A_FZD4_LRP5WNTHNSCCOSCC
WNT10AFZD6_LRP5WNT10A_FZD6_LRP5WNTHNSCCOSCC
WNT10AFZD6_LRP6WNT10A_FZD6_LRP6WNTHNSCCOSCC
WNT10AFZD6_LRP5WNT10A_FZD6_LRP5WNTHNSCCPrecancer
WNT10AFZD6_LRP6WNT10A_FZD6_LRP6WNTHNSCCPrecancer
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
WNT10ASNVMissense_Mutationnovelc.604A>Gp.Ser202Glyp.S202GQ9GZT5protein_codingtolerated(0.4)benign(0.006)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
WNT10ASNVMissense_Mutationrs779978162c.421G>Ap.Val141Metp.V141MQ9GZT5protein_codingdeleterious(0.01)probably_damaging(0.982)TCGA-DS-A0VL-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
WNT10ASNVMissense_Mutationc.775N>Tp.Arg259Trpp.R259WQ9GZT5protein_codingdeleterious(0)benign(0.096)TCGA-AZ-6599-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
WNT10ASNVMissense_Mutationc.73N>Tp.Leu25Phep.L25FQ9GZT5protein_codingdeleterious(0.02)possibly_damaging(0.587)TCGA-CK-4951-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
WNT10ASNVMissense_Mutationc.599C>Tp.Thr200Ilep.T200IQ9GZT5protein_codingtolerated(0.18)benign(0.085)TCGA-D5-5538-01Colorectumcolon adenocarcinomaFemale<65III/IVChemotherapycalciumPD
WNT10ASNVMissense_Mutationrs779978162c.421N>Ap.Val141Metp.V141MQ9GZT5protein_codingdeleterious(0.01)probably_damaging(0.982)TCGA-NH-A5IV-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
WNT10ASNVMissense_Mutationc.194C>Gp.Pro65Argp.P65RQ9GZT5protein_codingdeleterious(0)possibly_damaging(0.808)TCGA-QG-A5YV-01Colorectumcolon adenocarcinomaFemale<65III/IVChemotherapyxelodaCR
WNT10AinsertionFrame_Shift_Insnovelc.219_220insGTp.Arg77CysfsTer79p.R77Cfs*79Q9GZT5protein_codingTCGA-G4-6309-01Colorectumcolon adenocarcinomaFemale<65III/IVChemotherapyxelodaPD
WNT10ASNVMissense_Mutationnovelc.562N>Ap.Leu188Metp.L188MQ9GZT5protein_codingtolerated(0.63)benign(0.077)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
WNT10ASNVMissense_Mutationnovelc.497N>Gp.Asp166Glyp.D166GQ9GZT5protein_codingtolerated(0.13)benign(0.012)TCGA-A5-A0GP-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1